What’s Moving These Hot Stocks: Protalix, Endeavor International, CEVA
Protalix BioTherapeutics, Inc.’s (AMEX:PLX) early trade jump due to the FDA’s okay of its new med for Gaucher disease, is deflated somewhat by Canaccord, as the analyst downgrades shares to Hold. Reason for the move was said to be the report’s prediction of only modest domestic growth and the possibility that EU approval might get blocked. However, a solid growth potential in Israel remains a possibility.
Endeavor International Corporation (AMEX:END) posts first quarter revenue of $15.17 million, compared to a consensus of $15.44 million.
CEVA Inc.’s (NASDAQ:CEVA) first quarter revenue of $15.1 million beats consensus of $14.82 million.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.